Lecanemab
Treatment for Alzheimers Disease
Typical Dosage: 10 mg/kg intravenous infusion biweekly
Effectiveness
55%
Safety Score
50%
Clinical Trials
26
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
10 mg/kg intravenous infusion biweekly
Time to Effect
6-12 months
Treatment Duration
Ongoing
Evidence Quality
MODERATENumber Needed to Treat (NNT)
16(Treat 16 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$26,500
Monitoring:$8,000
Side Effect Mgmt:$2,000
Total Annual:$36,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$640,000/QALY
QALYs Gained
0.23
Comparison vs No treatment / symptomatic treatment
Cost Difference
+$36,500/year
More expensive
QALY Difference
+0.23 QALYs
Better outcomes
Dominance
No dominance
Lecanemab Outcomes
for Alzheimers Disease
Efficacy Outcomes
Overall Effectiveness
+55%
Common Side Effects
Infusion-related reactions
+26%
ARIA-E (edema)
+13%
ARIA-H (hemorrhage)
+17%
Headache
+13%
Sources:
Active Clinical Trials
19 active trials recruiting for Lecanemab in Alzheimers Disease
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
NCT06384573ACTIVE NOT RECRUITINGPHASE3
43 participants
INTERVENTIONAL
Birmingham, United States +5 more
Started: Jun 10, 2024
Feasibility of Lecanemab Registry and Clinical Outcome Measures
NCT06285448ENROLLING BY INVITATION
20 participants
OBSERVATIONAL
Saint Paul, United States
Started: Jan 2, 2024
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
NCT05269394ACTIVE NOT RECRUITINGPHASE2, PHASE3
197 participants
INTERVENTIONAL
Birmingham, United States +35 more
Started: Dec 22, 2021
The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.
NCT07212062NOT YET RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Started: Dec 1, 2025
Cognitive Neurology Unit Clinical Registry
NCT05925621RECRUITING
500 participants
OBSERVATIONAL
Boston, United States
Started: Jul 16, 2023
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258ACTIVE NOT RECRUITINGPHASE2
105 participants
INTERVENTIONAL
Phoenix, United States +25 more
Started: Sep 30, 2024
Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease
NCT06992804RECRUITINGEARLY_PHASE1
20 participants
INTERVENTIONAL
Beijing, China
Started: May 28, 2025
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455ACTIVE NOT RECRUITINGPHASE3
1.91K participants
INTERVENTIONAL
Phoenix, United States +246 more
Started: Mar 27, 2019
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659ACTIVE NOT RECRUITINGPHASE3
1.4K participants
INTERVENTIONAL
Birmingham, United States +108 more
Started: Jul 14, 2020
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
NCT05999084RECRUITING
735 participants
OBSERVATIONAL
Albany, United States +7 more
Started: Mar 6, 2025
Lecanemab for Early Onset Familial Alzheimer's Disease
NCT06883019RECRUITING
114 participants
OBSERVATIONAL
Beijing, China +14 more
Started: Mar 13, 2025
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01760005ACTIVE NOT RECRUITINGPHASE2, PHASE3
490 participants
INTERVENTIONAL
Birmingham, United States +37 more
Started: Dec 1, 2012
Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
NCT06741553RECRUITING
120 participants
OBSERVATIONAL
Hangzhou, China
Started: Jun 28, 2024
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
NCT06530732RECRUITINGPHASE3
60 participants
INTERVENTIONAL
Hangzhou, China
Started: Jul 1, 2024
A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease
NCT06810960RECRUITING
3K participants
OBSERVATIONAL
Nutley, United States
Started: Feb 24, 2025
Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research
NCT07152418NOT YET RECRUITING
120 participants
OBSERVATIONAL
Started: Sep 1, 2025
An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
NCT07153848RECRUITING
400 participants
OBSERVATIONAL
Hangzhou, China +1 more
Started: Jul 1, 2024
12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
NCT07034222ACTIVE NOT RECRUITINGPHASE4
80 participants
INTERVENTIONAL
Shanghai, China
Started: Feb 1, 2024
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
NCT06322667RECRUITING
5K participants
OBSERVATIONAL
Hiroshima, Japan +2 more
Started: Feb 14, 2024
Completed Clinical Trials
1 completed trial for Lecanemab in Alzheimers Disease
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
NCT01767311COMPLETEDPHASE2
856 participants
INTERVENTIONAL
Birmingham, United States +168 more
Started: Dec 20, 2012
Showing 20 of 26 total trials